Dasatinib
From Ganfyd
rINN: Dasatinib
Other Names
Sprycel®, BMS-354825
Pharmacological Information
Pharmacology Images
Web information on Dasatinib
Mechanism of Action
tyrosine kinase inhibitor
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Dasatinib (Less technical, good quality control)
Wikipedia on Dasatinib (Less technical, ? quality control)
Dasatinib is an ABL tyrosine kinase inhibitor. It has shown promising results in the treatment of chronic myeloid leukaemia (CML) and Ph-positive acute lymphoblastic leukaemia (ALL) that has become resistant to Imatinib[1][2][3].
Side-effects
- Pleural effusions
- Dyspnoea
- Cough
- Chest pain
References
- ↑ Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. The New England journal of medicine 2006;354(24):2531-41. (Direct link – subscription may be required.)
- ↑ Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. Blood 2007.(Epub ahead of print) (Direct link – subscription may be required.)
- ↑ Cannell E. Dasatinib is effective in imatinib-resistant CML. The lancet oncology 2007;8(4):286.
